메뉴 건너뛰기




Volumn 13, Issue 9, 2008, Pages 1021-1029

Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer

Author keywords

Angiogenesis inhibitors; Bevacizumab; Colorectal cancer; Fluorouracil; Monoclonal antibodies; Quality of life

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

EID: 52949151889     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0003     Document Type: Article
Times cited : (39)

References (17)
  • 1
    • 52949090626 scopus 로고    scopus 로고
    • Colon and Rectum Cancer. March 7, Available at, Accessed June 30, 2006
    • American Cancer Society. Detailed Guide: Colon and Rectum Cancer. March 7, 2006. Available at http://www.cancer.org/docroot/CRI/CRI_2_3x.asp?dt=10. Accessed June 30, 2006.
    • (2006) Detailed Guide
  • 2
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 3
    • 20544478429 scopus 로고    scopus 로고
    • Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial
    • Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705.
    • (2005) J Clin Oncol , vol.23 , pp. 3697-3705
    • Kabbinavar, F.F.1    Schulz, J.2    McCleod, M.3
  • 4
    • 0028939208 scopus 로고
    • Measuring quality of life in palliative care
    • Cella DF. Measuring quality of life in palliative care. Semin Oncol 1995;22(suppl 3):73-81.
    • (1995) Semin Oncol , vol.22 , Issue.SUPPL. 3 , pp. 73-81
    • Cella, D.F.1
  • 5
    • 52949120867 scopus 로고    scopus 로고
    • Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, Version 4. Evanston, IL: Center on Outcomes, Research & Education (CORE), Evanston Northwestern Healthcare and Northwestern University, 1997.
    • Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, Version 4. Evanston, IL: Center on Outcomes, Research & Education (CORE), Evanston Northwestern Healthcare and Northwestern University, 1997.
  • 6
    • 0032771187 scopus 로고    scopus 로고
    • Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument
    • Ward WL, Hahn EA, Mo F et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res 1999;8:181-195.
    • (1999) Qual Life Res , vol.8 , pp. 181-195
    • Ward, W.L.1    Hahn, E.A.2    Mo, F.3
  • 7
    • 0034727063 scopus 로고    scopus 로고
    • Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group
    • Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
    • (2000) N Engl J Med , vol.343 , pp. 905-914
    • Saltz, L.B.1    Cox, J.V.2    Blanke, C.3
  • 8
    • 0024385167 scopus 로고
    • The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. Gastrointestinal Tumor Study Group
    • Petrelli N, Douglass HO Jr, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989;7:1419-1426.
    • (1989) J Clin Oncol , vol.7 , pp. 1419-1426
    • Petrelli, N.1    Douglass Jr, H.O.2    Herrera, L.3
  • 9
    • 0036195669 scopus 로고    scopus 로고
    • Clinical Consensus Meeting Group. Methods to explain the clinical significance of health status measures
    • Guyatt GH, Osoba D, Wu AW et al.; Clinical Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:371-383.
    • (2002) Mayo Clin Proc , vol.77 , pp. 371-383
    • Guyatt, G.H.1    Osoba, D.2    Wu, A.W.3
  • 10
    • 0036184207 scopus 로고    scopus 로고
    • What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592
    • Cella D, Eton DT, Fairclough DL et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002;55:285-295.
    • (2002) J Clin Epidemiol , vol.55 , pp. 285-295
    • Cella, D.1    Eton, D.T.2    Fairclough, D.L.3
  • 11
    • 0036964529 scopus 로고    scopus 로고
    • Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales
    • Cella D, Eton DT, Lai JS et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-561.
    • (2002) J Pain Symptom Manage , vol.24 , pp. 547-561
    • Cella, D.1    Eton, D.T.2    Lai, J.S.3
  • 12
    • 0037304852 scopus 로고    scopus 로고
    • Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa
    • Patrick DL, Gagnon DD, Zagari MJ et al. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003;39:335-345.
    • (2003) Eur J Cancer , vol.39 , pp. 335-345
    • Patrick, D.L.1    Gagnon, D.D.2    Zagari, M.J.3
  • 13
    • 7044224362 scopus 로고    scopus 로고
    • A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale
    • Eton DT, Cella D, Yost KJ et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004;57:898-910.
    • (2004) J Clin Epidemiol , vol.57 , pp. 898-910
    • Eton, D.T.1    Cella, D.2    Yost, K.J.3
  • 14
    • 17744362659 scopus 로고    scopus 로고
    • Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)
    • Yost KJ, Yount SE, Eton DT et al. Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI). Breast Cancer Res Treat 2005;90:295-298.
    • (2005) Breast Cancer Res Treat , vol.90 , pp. 295-298
    • Yost, K.J.1    Yount, S.E.2    Eton, D.T.3
  • 15
    • 17144411798 scopus 로고    scopus 로고
    • Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument
    • Yost KJ, Sorensen MV, Hahn EA et al. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health 2005;8:117-127.
    • (2005) Value Health , vol.8 , pp. 117-127
    • Yost, K.J.1    Sorensen, M.V.2    Hahn, E.A.3
  • 16
    • 27744526720 scopus 로고    scopus 로고
    • Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches
    • Yost KJ, Cella D, Chawla A et al. Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches. J Clin Epidemiol 2005;58:1241-1251.
    • (2005) J Clin Epidemiol , vol.58 , pp. 1241-1251
    • Yost, K.J.1    Cella, D.2    Chawla, A.3
  • 17
    • 0002429117 scopus 로고
    • A confidence interval for the median survival time
    • Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29-41.
    • (1982) Biometrics , vol.38 , pp. 29-41
    • Brookmeyer, R.1    Crowley, J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.